Skip to search formSkip to main contentSkip to account menu

DNK 333

Known as: DNK-333, DNK333, N-((R,R)-(E)-1-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Aza CompoundsBenzamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Raznolikost mitohondrijske DNK divlje mačke u Hrvatskoj – preliminarni rezultati
2014
2014
Response to Keszthelyi and Masclee
To the Editor: We thank Keszthelyi and Masclee (1) for their interest in our study and are pleased to note that they agree with… 
2014
2014
Capsaicin Stimulation In Irritable Bowel Syndrome: Toward Understanding Visceral Perception and Pain Symptom Generation
Capsaicin Stimulation In Irritable Bowel Syndrome: Toward Understanding Visceral Perception and Pain Symptom Generation 
2011
2011
Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea‐predominant irritable bowel syndrome
Background  Neurokinin receptors may play an important role in the visceral hypersensitivity and exaggerated motor/secretory… 
Review
2007
Review
2007
Animal models of cough: literature review and presentation of a novel cigarette smoke-enhanced cough model in the guinea-pig.
Review
2006
Review
2006
When Knowledge is Not Enough: Hiv/Aids Information and Risky Behavior in Botswana
The spread of the HIV/AIDS epidemic is still fueled by ignorance in many parts of the world. Filling in knowledge gaps… 
Highly Cited
2004
Highly Cited
2004
Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A‐induced bronchoconstriction in asthma patients
Inhalation of neurokinin A (NKA) causes bronchoconstriction in patients with asthma. In vitro both tachykinin NK1 and NK2… 
2004
2004
The airways pharmacology of DNK333, a potent, selective, non‐peptide dual NK1/NK2 receptor antagonist
The airways' pharmacology of DNK333 ((1R,3R,2E)‐N‐[3,4‐dichlorobenzyl)]‐4‐[(hexahydro‐2‐oxo‐1H‐azepin‐3‐yl)amino]‐N‐methyl‐3,5bis… 
2003
2003
Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK…
In a program aimed at the development of neurokinin antagonists, N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl… 
2001
2001
Dual neurokinin NK(1)/NK(2) antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamides and 3-[N'-3,5-bis(trifluoromethyl)benzoyl-N…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)